好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Topline results from a randomized, placebo-controlled, Phase III study investigating the safety and efficacy of incobotulinumtoxinA in treating post-stroke spasticity of the upper limb
Neuro-rehabilitation
(-)
002
Authors/Disclosures
Kapil D. Sethi, MD, FRCP (UK), FAAN
PRESENTER 		Dr. Sethi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurocrine.
No disclosure on file
No disclosure on file
Daniel Ontaneda, MD, PhD, FAAN (Cleveland Clinic) Dr. Ontaneda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Ontaneda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech/Roche. Dr. Ontaneda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen Idec. Dr. Ontaneda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. The institution of Dr. Ontaneda has received research support from NIH. The institution of Dr. Ontaneda has received research support from PCORI. The institution of Dr. Ontaneda has received research support from NMSS. The institution of Dr. Ontaneda has received research support from Genetech.
Christina Marciniak, MD (Rehabilitation Institute of Chicago) No disclosure on file
Reinhard Hiersemenzel, MD (Merz Pharmaceuticals GmbH) No disclosure on file
No disclosure on file